Generation of beta cells from human pluripotent stem cells: Potential for regenerative medicine
► We reviewed recent progress on the generation of beta cells from hPSCs. ► We discussed the signaling pathways required for hPSC commitment to the pancreatic lineages. ► We discussed the importance of reproducing first and secondary transition in vitro. ► We discussed the generation of poly-hormona...
Gespeichert in:
Veröffentlicht in: | Seminars in cell & developmental biology 2012-08, Vol.23 (6), p.701-710 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | ► We reviewed recent progress on the generation of beta cells from hPSCs. ► We discussed the signaling pathways required for hPSC commitment to the pancreatic lineages. ► We discussed the importance of reproducing first and secondary transition in vitro. ► We discussed the generation of poly-hormonal cells in vitro, their potential role in embryonic development and the possibility to transdifferentiate these cells to beta cells. ► We identified current challenges and suggested potential approaches to generate functional beta cell in vitro from hPSCs.
The loss of beta cells in Type I diabetes ultimately leads to insulin dependence and major complications that are difficult to manage by insulin injections. Given the complications associated with long-term administration of insulin, cell-replacement therapy is now under consideration as an alternative treatment that may someday provide a cure for this disease. Over the past 10 years, islet transplantation trials have demonstrated that it is possible to replenish beta cell function in Type I diabetes patients and, at least temporarily, eliminate their dependency on insulin. While not yet optimal, the success of these trials has provided proof-of-principle that cell replacement therapy is a viable option for treating diabetes. Limited access to donor islets has launched a search for alternative source of beta cells for cell therapy purposes and focused the efforts of many investigators on the challenge of deriving such cells from human embryonic (hESCs) and induced pluripotent stem cells (hiPSCs). Over the past five years, significant advances have been made in understanding the signaling pathways that control lineage development from human pluripotent stem cells (hPSCs) and as a consequence, it is now possible to routinely generate insulin producing cells from both hESCs and hiPSCs. While these achievements are impressive, significant challenges do still exist, as the majority of insulin producing cells generated under these conditions are polyhormonal and non functional, likely reflecting the emergence of the polyhormonal population that is known to arise in the early embryo during the phase of pancreatic development known as the ‘first transition’. Functional beta cells, which arise during the second phase or transition of pancreatic development have been generated from hESCs, however they are detected only following transplantation of progenitor stage cells into immunocompromised mice. With this success, ou |
---|---|
ISSN: | 1084-9521 1096-3634 |
DOI: | 10.1016/j.semcdb.2012.06.010 |